Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus - Test2 - elhamkhani - TriplyDB

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

http://www.wikidata.org/entity/Q28261838

about

A quasi-spontaneous amyloid route in a DNA binding gene regulatory domain: The papillomavirus HPV16 E2 protein.Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review.Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses.Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial Immunotherapy for cervical cancer: Research status and clinical potential The influence of delivery vectors on HIV vaccine efficacy Using cancer incidence and mortality data to guide cancer control program The oncogenic potential of human papillomaviruses: a review on the role of host genetics and environmental cofactors.Immune therapy for human papillomaviruses-related cancers.Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial.Targeting the human papillomavirus E6 and E7 oncogenes through expression of the bovine papillomavirus type 1 E2 protein stimulates cellular motility.Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.The future of vaccines for cervical cancer.Therapeutic Vaccine Strategies against Human Papillomavirus.Progress in the development of a cervical cancer vaccine.Vaccines against cervical cancer.Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.Emerging human papillomavirus vaccines.Chemokine binding protein vCCI attenuates vaccinia virus without affecting the cellular response elicited by immunization with a recombinant vaccinia vector carrying the HPV16 E7 gene.Targeted treatments for cervical cancer: a review.Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.Human papillomavirus infection: an old disease, a new vaccine.Gene therapy in gynecological cancer.Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma.Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.Human papillomavirus therapeutic vaccines in head and neck tumors.Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.Progress and challenges in the vaccine-based treatment of head and neck cancers.Therapeutic vaccines against human papillomavirus and cervical cancer.Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis.Perspectives for the development of human papillomavirus vaccines and immunotherapy.Immunologic treatments for precancerous lesions and uterine cervical cancer.Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer.An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia.Current state in the development of candidate therapeutic HPV vaccines

P2860

Q30158017-ADA1E1D7-EA24-40C4-8DDA-6016944504AB Q30238779-BD29567A-D823-452E-BA80-ED3768DF786A Q33440600-5638BA0C-FE78-4EDA-9DC6-7BA768EDE9D2 Q33602820-F559DB45-63DE-47F1-B843-FBBE67867D12 Q33626255-20F31276-9CF3-47F5-BC49-9D47DF515558 Q34033763-6948AD47-F480-4767-9395-B88CC69A0E06 Q34077543-5B2F4A3A-7B16-4473-9A2C-D1E168E99A98 Q34367530-77E94DB3-48BF-46D9-B5D7-44ABA5D82D47 Q34635024-708F44E5-3E11-451F-A785-4983F7B9D87F Q34657561-2867BF1A-7EF9-417E-BAA3-8715C6F5A682 Q34729962-4343134C-CAD0-46D8-8115-F291E895AC1C Q35055665-22736593-1516-438E-AB89-C1D6356051C8 Q35274806-4C919B97-7E6D-4AD2-8A8A-9360AE8EB4E3 Q35751946-C8C84160-1EF7-4C78-B5B6-4A060F5E3636 Q35805491-013602E8-6CA9-4962-89F8-4B52D29D3A65 Q35826752-DF8ECCAE-CC0D-4901-934D-8437D8C0D4DC Q35919119-3D42B8C6-A033-4F62-B8D0-061D34C59290 Q35925621-1B6B39B9-7DB4-4BED-B52D-978AB2AA3228 Q35947683-8A9C02D4-84E8-4C43-A720-EA52C9A057C4 Q36066004-04FAE0B1-9793-4DC3-9AF9-49E161ADE1EB Q36305188-B53BB3C1-D99D-439C-A2D4-0E1A469D0A20 Q36384032-0D91BB2E-EEB1-483C-B90A-C11806DEFA51 Q36397581-C62088E3-A280-46FB-A371-532F2BC05979 Q36480555-13445642-B665-4E88-BBD9-7427B768CB7F Q36532089-37B370B2-CEA4-486F-8D34-6722F8E5A6F7 Q36541670-B9C9C3BC-5589-4F74-8CEE-D224DD561074 Q36628376-4DD78606-B8A7-488E-A9CF-2043FB463B59 Q36817148-28A1E511-0DF3-4F2D-A404-0139EA82ABC3 Q36849770-D3C2D70F-28C4-4B2E-8341-515A51A3E73E Q37118188-39DFE559-FA93-4275-8AA0-809ADBA71A12 Q37135023-6E5C75C1-A9EE-4FF7-B332-058C5579C6D6 Q37224926-94F92498-670D-4B6C-9C26-B7FE66E68E12 Q37418916-590F6EBB-4187-42E2-A830-49FD1033ACFB Q37545001-42F07945-6635-4646-AD25-51F2E314D8CB Q37579334-61F7526F-3727-41E5-9688-D932974F3485 Q37658876-A2EB1F75-EEF1-4142-BE7D-532507DB597D Q37703113-31FD9BC2-1DF4-4CDB-BBEE-A0E7E839E50F Q38089937-8D5E04F1-3E93-441F-8744-381A58A524CD Q38386055-A7980925-559A-4C2F-9DAE-39DB940865CC Q38743922-0DD79A3E-615B-41BB-B4A4-E9F3FB43BA2E

P2860

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

http://www.wikidata.org/entity/Q28261838

description

2004 nî lūn-bûn

@nan

2004 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Therapeutic vaccination with M ...... oncogenic human papillomavirus

@ast

Therapeutic vaccination with M ...... oncogenic human papillomavirus

@en

Therapeutic vaccination with M ...... oncogenic human papillomavirus

@nl

type

label

Therapeutic vaccination with M ...... oncogenic human papillomavirus

@ast

Therapeutic vaccination with M ...... oncogenic human papillomavirus

@en

Therapeutic vaccination with M ...... oncogenic human papillomavirus

@nl

prefLabel

Therapeutic vaccination with M ...... oncogenic human papillomavirus

@ast

Therapeutic vaccination with M ...... oncogenic human papillomavirus

@en

Therapeutic vaccination with M ...... oncogenic human papillomavirus

@nl

P1433

Q28261838-D153CCAC-703F-46E2-8673-F8A3CCE0F3AE

P1476

Q28261838-CB7841FC-4A29-41A0-9675-1A58043D2E23

P2093

Q28261838-1967C535-22AB-4E80-A35E-5A0A59EB1FB4

Q28261838-4A558C89-32C4-4C2B-B964-F4EE910F8D97

Q28261838-8E01AE36-D77D-48B3-BC7F-EDA3A7955088

Q28261838-93844DDA-0537-4F03-AF56-1BD5AF078442

Q28261838-9C5F28D9-18BE-450E-82B6-14493F4A921A

Q28261838-A0A79DC8-9280-4BE2-B6EE-AF5ED956F54E

Q28261838-BC6DBD65-B8BB-49D1-BAE3-925E95020E92

Q28261838-CAC9E36B-2E28-4289-99E9-15D97E064733

Q28261838-E1B1C7DB-A6EF-4263-9B6C-D59E5F7DEAA6

Q28261838-EDE61112-5204-4166-A394-C4F8BFB96F22

P304

Q28261838-E58B0B0B-77CB-4425-A5A6-7A930B6E1A1A

P31

Q28261838-B6BB7C6E-D136-4EFF-9334-8E0EB5B6F9FF

P356

Q28261838-0132B1BC-2B17-471E-AF65-3E3E0743549F

P407

Q28261838-02978A4C-03FC-43BC-8E15-3B0D2B8CB370

P433

Q28261838-8A24906D-A415-4617-B5A9-9A2F8425FD73

P478

Q28261838-EF990AB7-A19E-48B5-8317-138DC7CD3FFB

P577

Q28261838-868954C2-17CB-493C-A740-81C8A175A784

P698

Q28261838-7F1DAE0B-E3B9-4F46-B60C-8AFCE0B196B0

P356

10430340460745757

P1433

Human Gene Therapy

P1476

Therapeutic vaccination with M ...... oncogenic human papillomavirus

@en

P2093

Alberto Tinoco

http://www.w3.org/2001/XMLSchema#string

Carlos Manuel Corona Gutierrez

http://www.w3.org/2001/XMLSchema#string

Gianni Morosoli

http://www.w3.org/2001/XMLSchema#string

Lise Reyes

http://www.w3.org/2001/XMLSchema#string

Mario López Contreras

http://www.w3.org/2001/XMLSchema#string

Mauro Lara Verde

http://www.w3.org/2001/XMLSchema#string

Patricia Calzado

http://www.w3.org/2001/XMLSchema#string

Ricardo Rosales

http://www.w3.org/2001/XMLSchema#string

Roberto Posternak

http://www.w3.org/2001/XMLSchema#string

Roberto Risco Cortes

http://www.w3.org/2001/XMLSchema#string

P304

421-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/10430340460745757

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15144573

http://www.w3.org/2001/XMLSchema#string